Mydecine Innovations Group (OTCMKTS: MYCOF) has announced the engagement of JBN Partners LLC to boost public awareness and interest in the company, its products, and its management.
Mydecine hires public relations firm to enhance awareness
JBN will achieve this by coordinating specific investor relations and company financial public relations with the investor community, general public, and financial media. The JBN services agreement has six months and a total payment worth of $150,000.
Mydecine was created in 2020 to believe that there is a major unmet demand and a scarcity of innovation in the behavioral health and treatment fields. The company is committed to rapidly discovering novel therapies to treat PTSD, addiction, anxiety, depression, and other mental health conditions. The business approach of Mydecine Innovations Group includes clinical trials and data outcomes, scientific, technology, and regulatory knowledge, and a focus on psychedelic treatment supported by additional innovative compounds with distinct therapeutic potential.
Notably, Mydecine seeks to accelerate the development of novel medicines throughout its platforms by partnering with some of the world’s greatest authorities linked by best practices to effectively treat and ultimately change the way mental disorders are treated. Its mission is to close the gap between what the present cognitive healthcare system offers and what patients require.
Mydecine produces target-based models of psychedelic serotonin receptor 5-HT2A
The company has produced a target-based simulation of the iconic psychedelic serotonin receptor 5-HT2A for use in its AI-driven drug development program, the company said today. The new methodology will allow them to quickly screen billions of compounds to see which compounds are more likely to improve binding affinity, allowing them to continue developing better 2nd and 3rd generation psychedelic chemicals for medical usage.
Mydecine is positioned to develop therapeutic enhancements more cost-effectively and efficiently than its competitors by focusing its drug discovery efforts on machine learning (ML) and artificial intelligence (AI). AI and ML help the company to drastically cut or reduce the manual efforts undergone to identify potential drug improvements.
Curaleaf Holdings Inc (OTCMKTS: CURLF) Is Opening a Dispensary at State College
Post Views: 82 Curaleaf Holdings Inc (OTCMKTS: CURLF) is opening a State College Dispensary at 1248 A Atherton St, State...
Puration Inc (OTCMKTS: PURA) Is About to Make Its First Collaboration in the Asia Pacific
Post Views: 209 Puration Inc (OTCMKTS: PURA) is about to strike a deal for its first collaboration in the Asia...
Harborside Inc (OTCMKTS: HBORF) Will Convert Multiple Voting Shares Into Subordinate Voting Shares
Post Views: 1,711 Harborside Inc (OTCMKTS: HBORF) has announced that it will convert its outstanding and issued multiple voting shares...
Trulieve Cannabis Corp (OTCMKTS: TCNNF) Announces Partnership With Khalifa Kush
Post Views: 234 Trulieve Cannabis Corp (OTCMKTS: TCNNF) Khalifa Kush has announced an exclusive partnership. Khalifa Kush is a brand...
Indiva Ltd (OTCMKTS: NDVAF) Launches Jewel Cannabis Tarts
Post Views: 135 Indiva Ltd (OTCMKTS: NDVAF) recently launched Jewel Cannabis Tarts, its latest products into the cannabis Industry. The...
Neptune Wellness Solutions Inc’s (NASDAQ: NEPT) Subsidiary, Sprout Organics, Executes a Partnership With Cocomelon for the Distribution of Organic Produce
Post Views: 61 Sprout Organics, a subsidiary of Neptune Wellness Solutions Inc (NASDAQ; NEPT), recently announced the execution of its...